Contemporary epidemiology of gout in the UK general population

Lucía Cea Soriano, Dietrich Rothenbacher, Hyon K Choi, Luis A García Rodríguez, Lucía Cea Soriano, Dietrich Rothenbacher, Hyon K Choi, Luis A García Rodríguez

Abstract

Introduction: The objective of this study was to investigate the contemporary incidence of gout, examine potential risk factors, and evaluate specific gout treatment patterns in the general population.

Methods: Using the health improvement network (THIN) UK primary care database, we estimated the incidence of gout based on 24,768 newly diagnosed gout patients among a cohort of 1,775,505 individuals aged 20 to 89 years between 2000 and 2007. We evaluated potential risk factors for incident gout in a nested case-control study with 50,000 controls frequency-matched by age, sex and calendar time. We calculated odds ratios (OR) by means of unconditional logistic regression adjusting for demographic variables, lifestyle variables, relevant medical conditions and drug exposures.

Results: The incidence of gout per 1,000 person-years was 2.68 (4.42 in men and 1.32 in women) and increased with age. Conventional risk factors were significantly and strongly associated with the risk of gout, with multivariate ORs of 3.00 (95% confidence interval (CI)) for excessive alcohol intake (that is, more than 42 units per week), 2.34 (95% CI 2.22 to 2.47) for obesity (body mass index > = 30 kg/m2), 2.48 (95% CI 2.19 to 2.81) for chronic renal impairment, and 3.00 (95% CI 2.85 to 3.15) for current diuretic use. For other medical conditions the multivariate OR were 1.84 (95% CI 1.70 to 2.00) for heart failure, 1.45 (95% CI 1.18 to 1.79) for hypertriglyceridemia and 1.12 (95% CI 1.04 to 1.22) for psoriasis. Use of cyclosporine was associated with an OR of 3.72 (95% CI, 2.17 to 6.40). Among gout-specific therapies, allopurinol was the most frequently used with a one-year cumulative incidence of 28% in a cohort of incident gout diagnosed from 2000 to 2001. Use of gout-specific treatment has not changed over recent years except for an increase of colchicine.

Conclusions: The contemporary incidence of gout in UK remains substantial. In this general population cohort, associations with previously purported risk factors were evident including psoriasis, heart failure, hypertriglyceridemia, and cyclosporine therapy. Use of gout-specific treatment has remained relatively constant in recent years except for an increase of colchicine.

Figures

Figure 1
Figure 1
Sex and age specific incidence rate of gout 2000 to 2007 in the THIN database. Incidence rates per 1,000 person-years: overall 2.68 (95% CI 2.65 to 2.72), men 4.42 (95% CI 4.36 to 4.48), women 1.32 (95% CI 1.29 to 1.35)
Figure 2
Figure 2
Sex and age specific incidence rate of gout in 2000/2001 and 2006/2007. 2000 to 2001: Incidence rates per 1,000 person-years: overall 2.67 (95% CI 2.59 to 2.75), men 4.48 (95% CI 4.33 to 4.64), women 1.28 (95% CI 1.21 to 1.35). 2006 to 2007: Incidence rates per 1,000 person-years: overall 2.52 (95% CI 2.46 to 2.57), men 4.01 (95% CI 3.91 to 4.12), women 1.25 (95% CI 1.20 to 1.30).
Figure 3
Figure 3
Cumulative incidence of gout treatment over gout disease duration.
Figure 4
Figure 4
One-year cumulative incidence of gout treatment in 2000 to 2001 and 2006 to 2007.

References

    1. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HRJ, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 2005;64:267–272. doi: 10.1136/ard.2004.024091.
    1. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003;349:1647–1655. doi: 10.1056/NEJMcp030733.
    1. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499–516.
    1. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11:S435–442. quiz S465-468.
    1. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007;66:1311–1315. doi: 10.1136/ard.2007.070755.
    1. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis. 2006;65:1312–1324. doi: 10.1136/ard.2006.055269.
    1. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403–2406.
    1. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67:960–966. doi: 10.1136/ard.2007.076232.
    1. Elliot AJ, Cross KW, Fleming DM. Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007. Ann Rheum Dis. 2009;68:1728–1733. doi: 10.1136/ard.2008.096693.
    1. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165:742–748. doi: 10.1001/archinte.165.7.742.
    1. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12:171–177.
    1. Meier CR, Jick H. Omeprazole, other antiulcer drugs and newly diagnosed gout. Br J Clin Pharmacol. 1997;44:175–178. doi: 10.1046/j.1365-2125.1997.00647.x.
    1. Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Gout and risk of Parkinson disease: a prospective study. Neurology. 2007;69:1696–1700. doi: 10.1212/01.wnl.0000279518.10072.df.
    1. Hak AE, Curhan G, Grodstein FD, Choi HK. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2009;69:1305–1309. doi: 10.1136/ard.2009.109884.
    1. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, Chan KA, Roblin D, Raebel MA, Von Worley A, Platt R, Saag KG. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65:1368–1372. doi: 10.1136/ard.2006.051649.
    1. Atallah AN, Guimaraes JA, Gebara M, Sustovich DR, Martinez TR, Camano L. Progesterone increases glomerular filtration rate, urinary kallikrein excretion and uric acid clearance in normal women. Braz J Med Biol Res. 1988;21:71–74.
    1. Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women--the Third National Health and Nutrition Examination Survey. Arthritis Res Ther. 2008;10:R116. doi: 10.1186/ar2519.
    1. Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J. 1973;1:449–451. doi: 10.1136/bmj.1.5851.449.
    1. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol. 2005;17:341–345. doi: 10.1097/01.cco.0000152664.87204.3c.
    1. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998;57:509–510. doi: 10.1136/ard.57.9.509.
    1. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277–1281. doi: 10.1016/S0140-6736(04)16000-5.
    1. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57:109–115. doi: 10.1002/art.22466.
    1. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8:S2. doi: 10.1186/ar1907.
    1. Rodriguez G, Soriano LC, Choi HK. Impact of diabetes against the future risk of developing gout. Ann Rheum Dis. 2010;69:2090–2094. doi: 10.1136/ard.2010.130013.
    1. Choi HK, Ford ES. Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels--the Third National Health and Nutrition Examination Survey. Rheumatology (Oxford) 2008;47:713–717. doi: 10.1093/rheumatology/ken066.
    1. Ketai LH, Simon RH, Kreit JW, Grum CM. Plasma hypoxanthine and exercise. Am Rev Respir Dis. 1987;136:98–101.
    1. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC, Coats AJ. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18:858–865.
    1. Janssens HJ, van de Lisdonk EH, Janssen M, van den Hoogen HJ, Verbeek AL. Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis. 2006;65:1080–1083. doi: 10.1136/ard.2005.040360.
    1. Pascual E, Perdiguero M. Gout, diuretics and the kidney. Ann Rheum Dis. 2006;65:981–982. doi: 10.1136/ard.2005.049023.
    1. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. Kidney Int. 2003;64:1022–1026. doi: 10.1046/j.1523-1755.2003.t01-2-00171.x.
    1. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40:37–42. doi: 10.1053/ajkd.2002.33911.
    1. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11:974–979.
    1. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989;321:287–292. doi: 10.1056/NEJM198908033210504.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅